

# Hajime Yoshisue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/909850/publications.pdf>

Version: 2024-02-01

9  
papers

127  
citations

1478505

6  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

216  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence. <i>Value in Health Regional Issues</i> , 2022, 27, 41-48.	1.2	1
2	Clinical Characteristics, Health Care Resource Utilization, and Prescription Patterns of Japanese Patients with Physician-Diagnosed Allergic Rhinitis: A Secondary Use of Database Study. <i>International Archives of Allergy and Immunology</i> , 2022, 183, 953-966.	2.1	2
3	Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance. <i>Allergology International</i> , 2021, 70, 319-326.	3.3	11
4	Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000856.	3.0	7
5	Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. <i>Respirology</i> , 2020, 25, 393-400.	2.3	13
6	Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: A post-marketing surveillance. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101950.	2.6	7
7	Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. <i>Advances in Therapy</i> , 2019, 36, 495-519.	2.9	12
8	COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan. <i>International Journal of COPD</i> , 2018, Volume 13, 2629-2641.	2.3	14
9	Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. <i>Respiratory Medicine</i> , 2018, 141, 56-63.	2.9	60